

ASX Announcement

Extension to Share Purchase Plan Closing Date

Sydney, Australia, 20 July 2026: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**) (**Recce or the Company**), has extended the closing date of its current share purchase plan (**SPP**) announced on 26 June 2026 to **5:00pm (AEST) on Friday 24 July 2026**.

The SPP provides eligible shareholders an opportunity to purchase up to A\$30,000 worth of fully paid ordinary shares (**Shares**) at an issue price of A\$0.40 per Share irrespective of the size of their shareholding in Recce, without incurring brokerage or transaction costs. The extension of the SPP is to ensure that all eligible shareholders have sufficient time to participate.

Applicants under the SPP will also be invited to apply for one (1) free attaching unlisted option for every two (2) Shares subscribed for in the SPP with an exercise price of A\$0.60 and expiring 30 June 2027 (**Attaching Options**). Each Attaching Option gives the holder a right to receive, upon exercise and payment of the exercise price, one (1) Share and two (2) free unlisted options with an exercise price of A\$1.00 and expiring 30 June 2028 (**Piggyback Options**). Each Piggyback Option gives the holder the right to receive one (1) Share upon exercise and payment of the exercise price. The issue of the Attaching Options and Piggyback Options is subject to shareholder approval at an upcoming general meeting, with the offer to be made under a separate options prospectus issued under the *Corporations Act 2001* (Cth), which is expected to be lodged with ASIC and ASX on or about Wednesday, 2 September 2026.

Further details are outlined in the SPP Offer Booklet, which should be read in full before determining whether to subscribe for Shares under the SPP Offer.

The revised timetable for completion of the SPP is as follows, with the revised dates highlighted in blue:



ASX: RCE, FSE: R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 T +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Event	Date*
SPP Record Date	7:00pm (AEST), Thursday, 25 June 2026
SPP Offer Booklet made available to eligible shareholders and SPP Offer open date	Monday, 6 July 2026
<i>Revised</i> SPP offer closing date	5:00pm (AEST) Friday, 24 July 2026
<i>Revised</i> Last day to announce results of SPP	Friday, 31 July 2026
<i>Revised</i> Allotment and issue of new shares under the SPP	Friday, 31 July 2026
<i>Revised</i> Commencement of trading of new shares under the SPP	Monday, 3 August 2026
General Meeting (GM)	On or about Monday, 31 August 2026
Lodgement of Prospectus with ASIC and ASX in relation to Attaching Options and Piggyback Options	On or about Wednesday, 2 September 2026

**The timetable is indicative only and may change. The Company reserves the right to amend these dates and times, subject to applicable laws and the ASX Listing Rules. The Company may, at its sole and absolute discretion, close the SPP early or accept late applications if it considers it necessary, by announcing the change to ASX. The commencement and quotation of Shares offered under the SPP are subject to ASX confirmation. Recce also reserves the right, at its absolute discretion, to place any SPP shortfall with institutional or sophisticated investors.*

An updated Appendix 3B was released to ASX at or about the same time as this announcement.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.